Show simple item record

dc.contributor.authorChurchyard, Gavin
dc.contributor.authorCárdenas, Vicky
dc.contributor.authorChihota, Violet
dc.contributor.authorMngadi, Kathy
dc.contributor.authorSebe, Modulakgotla
dc.contributor.authorBrumskine, William
dc.contributor.authorMartinson, Neil
dc.contributor.authorYimer, Getnet
dc.contributor.authorWang, Shu-Hua
dc.contributor.authorGarcia-Basteiro, Alberto L
dc.contributor.authorNguenha, Dinis
dc.contributor.authorMasilela, LeeAnne
dc.contributor.authorWaggie, Zainab
dc.contributor.authorvan den Hof, Susan
dc.contributor.authorCharalambous, Salome
dc.contributor.authorCobelens, Frank
dc.contributor.authorChaisson, Richard E
dc.contributor.authorGrant, Alison D
dc.contributor.authorFielding, Katherine L
dc.date.accessioned2021-09-13T12:45:34Z
dc.date.available2021-09-13T12:45:34Z
dc.date.issued2021-08-24
dc.identifier.pmid34424730
dc.identifier.doi10.7326/M20-7577
dc.identifier.urihttp://hdl.handle.net/10029/625255
dc.description.abstractBetween November 2016 and November 2017, 4027 participants were enrolled; 4014 were included in the analyses (median age, 41 years; 69.5% women; all using antiretroviral therapy). Treatment completion in the first year for the combined rifapentine-isoniazid groups (n = 3610) was 90.4% versus 50.5% for the isoniazid group (n = 404) (risk ratio, 1.78 [95% CI, 1.61 to 1.95]). Tuberculosis incidence among participants receiving the rifapentine-isoniazid regimen twice (n = 1808) or once (n = 1802) was similar (hazard ratio, 0.96 [CI, 0.61 to 1.50]).en_US
dc.language.isoenen_US
dc.titleAnnual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.en_US
dc.typeArticleen_US
dc.identifier.eissn1539-3704
dc.identifier.journalAnn Intern Med 2021; advance online publication (ahead of print)en_US
dc.source.journaltitleAnnals of internal medicine
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record